Publication Name	World Journal of Gastroenterology
Manuscript ID	39053
Country	Spain

Category	Gastroenterology & Hepatology
Manuscript Type	Review
Article Title	Is it possible to stop nucleos(t)ide analogue treatment in chronic hepatitis B patients?
Manuscript Source	Invited Manuscript
All Author List	Elia Moreno-Cubero, Robert Sánchez-del-Arco, Julia Peña-Asensio, Eduardo Sanz-de-Villalobos, Joaquín Miquel and Juan Ramón Larrubia
Funding Agency and Grant Number	Funding Agency Grant Number Gilead Spain & Instituto de Salud Carlos III GLD14_00217 Gilead Spain & Instituto de Salud Carlos III GLD16_00014 Instituto de Salud Carlos III, Spain & European Regional Development Fund (ERDF), a way of making Europe PI12/00130 Instituto de Salud Carlos III, Spain & European Regional Development Fund (ERDF), a way of making Europe PI15/00074
Corresponding Author	Juan Ramón Larrubia, MD, MSc, PhD, Senior Lecturer, Staff Physician, Translational Hepatology Unit, Guadalajara University Hospital, University of Alcalá, Donante de Sangre st, Guadalajara E-19002, Spain. juan.larrubia@uah.es
Key Words	CD8; Lamivudine; Nucleos(t)ide analogues; Tenofovir; Chronic hepatitis B; Entecavir; hepatitis B virus; Treatment cessation
Core Tip	Nucleos(t)ide analogue (NA) treatment effi­ciently suppress hepatitis B virus replication. However, hepatitis B surface antigen loss, the optimal endpoint of NA therapy, is rarely achieved. Thus, a major unmet need in the management of chronic hepatitis B is the definition of earlier and safe treatment stopping points. There is growing clinical evidence that the majority of patients can benefit from this strategy after long-term NA therapy; yet, no criteria that distinguish which cases can safely stop treatment is established. We review here different biomarkers that could serve as a prognostic tool to safely discontinue therapy, focusing on host antiviral immunity.
Citation	Moreno-Cubero E, Sánchez del Arco RT, Peña-Asensio J, Sanz de Villalobos E, Míquel J, Larrubia JR. Is it possible to stop nucleos(t)ide analogue treatment in chronic hepatitis B patients? World J Gastroenterol 2018; 24(17): 1825-1838

Received	2018-04-02 03:22
Peer-Review Started	2018-04-02 07:10
To Make the First Decision	2018-04-19 01:23
Return for Revision	2018-04-21 08:49
Revised	2018-04-21 17:37
Second Decision	2018-04-23 05:30
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2018-04-23 16:28
Articles in Press	2018-04-23 16:28
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2018-05-04 10:00

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved.
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com